Max Biopharma, Inc.
Santa Monica, CA
- UEI
- NZ8XY5DKRAD3
- CAGE
- 67CG2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2870 Colorado Ave, Santa Monica, CA 90404, USA
- Website
- maxbiopharma.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Business | Del Mar, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Ortholevo, Inc. | Lynnfield, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Microcures Inc. | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Max Biopharma, Inc. is a for-profit biopharmaceutical company that provides drug and device development services to the federal government through research and development project grants from agencies within the Department of Health and Human Services. Max Biopharma specializes in developing novel therapeutics targeting fibrosis, inflammation, and tissue regeneration.
Through prime federal grants from the National Institutes of Health, Max Biopharma has conducted research and development of drug candidates and combination drug-device products for treating non-alcoholic steatohepatitis, idiopathic pulmonary fibrosis, atherosclerosis, spine fusion, and other conditions. Specific activities funded include efficacy testing, safety studies, formulation optimization, and other work required for Investigational New Drug applications across multiple NIH grant programs including the National Institute of Diabetes and Digestive and Kidney Diseases, National Heart Lung and Blood Institute, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. Key drug candidates and products Max Biopharma has advanced through federal grants include the anti-fibrotic compound Oxy210 for liver, lung, and cardiovascular disease; the osteoinductive small molecule Oxy133 as an alternative bone growth factor for spine fusion procedures; and proprietary oxysterol-based signaling pathway inhibitors for targeting organ fibrosis.
SBA capabilities narrative
MAX BioPharma Inc is a small business located in Santa Monica, CA. Company delivers consistent and quality Research and Development in Nanotechnology to its customers with the highest level of integrity and great attention to people, products, and service. They are passionate about their business and go to extraordinary lengths to satisfy their customers. Company's vision is to create and strengthen relationships with their customers by providing exceptional service and consistently demonstrating their quality services. Company and its employees take great pride in their work and in delighting their customers.
Quick answers
Is Max Biopharma, Inc. registered in SAM.gov?
Yes. Max Biopharma, Inc.'s SAM.gov registration is active through November 11, 2026.
What is Max Biopharma, Inc.'s most recent federal award?
Max Biopharma, Inc.'s most recent federal grant award is Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, OXY210, as a therapeutic drug candidate for… (R44DK136405), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on May 1, 2023.
On GovTribe
See Max Biopharma, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors